Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by First Western Trust Bank

First Western Trust Bank decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,020 shares of the medical research company's stock after selling 847 shares during the quarter. Thermo Fisher Scientific accounts for about 0.3% of First Western Trust Bank's holdings, making the stock its 27th biggest holding. First Western Trust Bank's holdings in Thermo Fisher Scientific were worth $5,733,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in Thermo Fisher Scientific by 1.7% during the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock worth $4,719,477,000 after purchasing an additional 127,564 shares in the last quarter. Coldstream Capital Management Inc. boosted its stake in Thermo Fisher Scientific by 11.4% in the third quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock valued at $5,972,000 after acquiring an additional 995 shares in the last quarter. Greenwood Gearhart Inc. grew its holdings in shares of Thermo Fisher Scientific by 9.8% during the third quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock worth $12,730,000 after purchasing an additional 1,837 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Thermo Fisher Scientific by 23.6% in the 4th quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock valued at $28,868,000 after purchasing an additional 10,606 shares during the last quarter. Finally, S.E.E.D. Planning Group LLC grew its stake in Thermo Fisher Scientific by 6.2% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock worth $5,528,000 after buying an additional 618 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company's stock, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock valued at $13,106,062 in the last quarter. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded up $1.54 during trading hours on Wednesday, hitting $420.85. The stock had a trading volume of 1,506,704 shares, compared to its average volume of 1,666,473. The stock has a market capitalization of $158.77 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1-year low of $410.49 and a 1-year high of $627.88. The stock's fifty day moving average is $522.77 and its two-hundred day moving average is $543.48.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.41%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific's payout ratio is presently 10.41%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TMO shares. Wells Fargo & Company increased their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Scotiabank raised their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research report on Monday, February 3rd. StockNews.com raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Morgan Stanley upped their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Finally, Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.